IRLAB Therapeutics advances towards Phase III trial for mesdopetam neurological treatment.
IRLAB Therapeutics has announced significant advancements in its preparations for the Phase III clinical trial of mesdopetam, a treatment aimed at addressing neurological conditions. The report highlights the company's commitment to progressing this therapy, which could potentially impact patient care. Further details on the trial design and expected timelines were not provided.
October 29, 2024
3 Articles